Jump Financial, LLC Fibrogen Inc Transaction History

Jump Financial, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$0.33 - $1.26 $4,783 - $18,264	-14,496 Closed	0 $0
Q2 2024 Aug 14, 2024	BUY	$0.89 - $2.36 $12,901 - $34,210	14,496 New	14,496 $12,000
Q2 2023 Oct 21, 2024	SELL	$2.49 - $20.59 $100,175 - $828,356	-40,231 Reduced 74.26%	13,943 $37,000
Q2 2023 Aug 07, 2023	SELL	$2.49 - $20.59 $100,175 - $828,356	-40,231 Reduced 74.26%	13,943 $37,000
Q1 2023 Oct 21, 2024	BUY	$15.95 - $25.18 $632,864 - $999,092	39,678 Added 273.72%	54,174 $1.01 Million
Q1 2023 May 03, 2023	BUY	$15.95 - $25.18 $864,075 - $1.36 Million	54,174 New	54,174 $1.01 Million
Q3 2022 Nov 07, 2022	BUY	$11.4 - $14.6 $161,880 - $207,320	14,200 New	14,200 $185,000
Q1 2022 May 12, 2022	SELL	$12.02 - $16.79 $408,908 - $571,179	-34,019 Closed	0 $0
Q4 2021 Feb 10, 2022	SELL	$9.93 - $15.39 $618,450 - $958,504	-62,281 Reduced 64.67%	34,019 $479,000
Q3 2021 Nov 12, 2021	BUY	$10.18 - $26.64 $980,334 - $2.57 Million	96,300 New	96,300 $984,000

47.1M

387K

672K

Ticker FGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 93,741,200
Market Cap $32.8M
Description
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic k...

Get notified when there are updates to the investment portfolio of Jump Financial, LLC, based on Form 13F filings with the SEC.

Stay updated on Jump Financial, LLC with notifications on news.